FDA panel rejects combination pain pill

Federal health advisers have unanimously rejected an experimental pain pill that combines two common opioids, oxycodone and morphine.

The , Moxduo, was developed by QRxPharma with the aim of decreasing dangerous side effects of , including , nausea and vomiting. The company theorized that combining lower doses of the two drugs would be safer and more effective than taking higher doses of the drugs separately.

But FDA advisers say that the company's studies of Moxduo did not show any advantages over regular oxycodone and morphine.

The FDA's 14 pain specialists all voted against approving the drug. The FDA is not required to follow the panel's recommendation.

A half-dozen public speakers urged the FDA to reject the drug at the Tuesday meeting, citing its potential for abuse.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA advisers unanimously back J&J hepatitis C drug

Oct 24, 2013

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

US panel opposes pure hydrocodone painkiller

Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

19 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments